MC2308A1 - Peptides utilises dans la vaccination et l'induction d'anticorps neutralisant contre le virus de l'immunodeficience humaine - Google Patents

Peptides utilises dans la vaccination et l'induction d'anticorps neutralisant contre le virus de l'immunodeficience humaine

Info

Publication number
MC2308A1
MC2308A1 MC912308D MC2308D MC2308A1 MC 2308 A1 MC2308 A1 MC 2308A1 MC 912308 D MC912308 D MC 912308D MC 2308 D MC2308 D MC 2308D MC 2308 A1 MC2308 A1 MC 2308A1
Authority
MC
Monaco
Prior art keywords
peptides
immunodeficiency virus
human immunodeficiency
against human
vaccination
Prior art date
Application number
MC912308D
Other languages
English (en)
Inventor
Anders Vahlne
Bo Svennerholm
Lars Rymo
Stig Jeansson
Peter Horal
Original Assignee
Syntello Vaccine Dev Kb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntello Vaccine Dev Kb filed Critical Syntello Vaccine Dev Kb
Publication of MC2308A1 publication Critical patent/MC2308A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MC912308D 1990-09-27 1991-09-27 Peptides utilises dans la vaccination et l'induction d'anticorps neutralisant contre le virus de l'immunodeficience humaine MC2308A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58942290A 1990-09-27 1990-09-27

Publications (1)

Publication Number Publication Date
MC2308A1 true MC2308A1 (fr) 1993-09-27

Family

ID=24357953

Family Applications (1)

Application Number Title Priority Date Filing Date
MC912308D MC2308A1 (fr) 1990-09-27 1991-09-27 Peptides utilises dans la vaccination et l'induction d'anticorps neutralisant contre le virus de l'immunodeficience humaine

Country Status (13)

Country Link
US (1) US5589175A (fr)
EP (1) EP0550599B1 (fr)
JP (1) JPH06501260A (fr)
AT (1) ATE238065T1 (fr)
AU (1) AU650911B2 (fr)
CA (1) CA2091263C (fr)
DE (1) DE69133242T2 (fr)
ES (1) ES2194836T3 (fr)
FI (1) FI931393A0 (fr)
HU (1) HU9300877D0 (fr)
MC (1) MC2308A1 (fr)
OA (1) OA09802A (fr)
WO (1) WO1992005800A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939074A (en) * 1986-12-30 1999-08-17 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptide antigens
US5346989A (en) * 1990-08-22 1994-09-13 Syntello Vaccine Development Kb Peptides for use in induction of T cell activation against HIV-1
WO1992021377A1 (fr) * 1991-06-03 1992-12-10 Syntello Inc. Peptides a utiliser pour induire l'activation de lymphocytes t contre le vih-1
ES2257733T3 (es) * 1991-08-29 2006-08-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Antigenos peptidicos multideterminantes que estimulan la respuesta de los linfocitos auxiliares al hiv en una amplia gama de humanos.
IT1254360B (it) * 1992-05-11 1995-09-14 San Romanello Centro Fond Epitopi immunologicamente omologhi di hla e proteine del virus hiv.
DE4228787A1 (de) * 1992-08-29 1994-03-03 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Neue HIV-1-Virusisolate eines Subtyps, Vakzine gegen HIV-1-Virusinfektionen dieses Subtyps und Verfahren zu ihrer Herstellung, Verwendung der HIV-1-Virusisolate
WO1994023746A1 (fr) * 1993-04-16 1994-10-27 Syntello Vaccine Development Ab Peptides utilises pour la vaccination et pour l'induction d'anticorps neutralisants diriges contre le virus d'immunodeficience humaine
FR2707170A1 (fr) * 1993-06-04 1995-01-13 Pasteur Institut Expression des récepteurs CD4 et CD26 dans des cellules recombinantes, inhibiteurs du récepteur CD26.
FR2707169B1 (fr) * 1993-06-04 1995-09-01 Pasteur Institut Antigène cellulaire CD26 impliqué dans l'infection par un rétrovirus hiv. nouveaux inhibiteurs de l'infection par HIV. * (Dipeptidyl-peptidase IV).
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
AU2991197A (en) * 1996-04-15 1997-11-07 University Of North Carolina At Chapel Hill, The Antigenic sequences of a sperm protein and immunocontraceptive methods
US7048929B1 (en) * 1997-11-10 2006-05-23 Dana-Farber Cancer Institute, Inc. Stabilized primate lentivirus envelope glycoproteins
ES2657480T3 (es) 2006-08-11 2018-03-05 Life Sciences Research Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
CA2715611C (fr) 2008-02-14 2018-03-13 Life Sciences Research Partners Vzw Immunotherapie ciblant des agents pathogenes intracellulaires
EP2623115A1 (fr) 2008-02-14 2013-08-07 Life Sciences Research Partners VZW Contrôle immunogène de tumeurs et cellules tumorales
HUE055070T2 (hu) * 2010-11-25 2021-10-28 Imnate Sarl Immunogén peptidek fertõzõ betegségek, autoimmun betegségek, allofaktorokra adott immunválaszok, allergiás betegségek, tumorok, graftkilökõdés, és génterápiához vagy génvakcinációhoz alkalmazott vírusvektorokkal szembeni immunválaszok megelõzésében és/vagy kezelésében történõ alkalmazásra
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
ES2874077T3 (es) 2015-09-25 2021-11-04 Imcyse Sa Métodos y compuestos mejorados para eliminar respuestas inmunitarias a agentes terapéuticos
KR20240015731A (ko) 2016-04-19 2024-02-05 임시스 에스에이 신규 면역원성 CD1d 결합 펩티드

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3588248T2 (de) * 1984-10-18 2004-07-01 Institut Pasteur LAV-Antigene und -Peptide
AU617088B2 (en) * 1986-06-12 1991-11-21 Biogen, Inc. Peptides involved in the pathogenesis of hiv infection
US5128319A (en) * 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
US5019387A (en) * 1987-09-08 1991-05-28 Duke University Production of antibodies to HIV
WO1989005820A1 (fr) * 1987-12-21 1989-06-29 Arch Development Corporation Antigenes et anticorps associes au virus d'immunodeficience humaine
EP0330359A3 (fr) * 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Composition utile pour le diagnostic et le traitement de l'infection par le HIV-I
AU3557889A (en) * 1988-04-20 1989-11-24 Trustees Of The University Of Pennsylvania, The Protective peptides derived from human immunodeficiency virus-1 gp160
US4943628A (en) * 1988-06-13 1990-07-24 Ortho Pharmaceutical Corporation HIV peptide-inducted T cell stimulation
WO1991015512A2 (fr) * 1990-04-03 1991-10-17 Genentech, Inc. Polypeptides d'enveloppe du vih
AP237A (en) * 1990-05-29 1993-04-29 Cedars Sinai Medical Center Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type 1 (HIV-1) gp120 and methods of use.
WO1992021377A1 (fr) * 1991-06-03 1992-12-10 Syntello Inc. Peptides a utiliser pour induire l'activation de lymphocytes t contre le vih-1

Also Published As

Publication number Publication date
US5589175A (en) 1996-12-31
OA09802A (en) 1994-04-15
CA2091263C (fr) 2003-05-06
FI931393A (fi) 1993-03-26
WO1992005800A1 (fr) 1992-04-16
ATE238065T1 (de) 2003-05-15
AU650911B2 (en) 1994-07-07
ES2194836T3 (es) 2003-12-01
JPH06501260A (ja) 1994-02-10
EP0550599A1 (fr) 1993-07-14
DE69133242D1 (de) 2003-05-28
DE69133242T2 (de) 2004-02-19
CA2091263A1 (fr) 1992-03-28
EP0550599B1 (fr) 2003-04-23
AU8643591A (en) 1992-04-28
FI931393A0 (fi) 1993-03-26
HU9300877D0 (en) 1993-06-28

Similar Documents

Publication Publication Date Title
MC2308A1 (fr) Peptides utilises dans la vaccination et l'induction d'anticorps neutralisant contre le virus de l'immunodeficience humaine
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
BR9814487A (pt) "vacina"
DK0891982T3 (da) HIV-peptider
ES2013328A6 (es) Un metodo para detectar anticuerpos contra antigenos hiv-1.
DE69434499D1 (de) Monoklonale Antikörper und Fv gegen das CD2 Antigen
TR199801722T2 (xx) Peptit imm�nojenler.
FR2603107A1 (fr) Compositions, vaccin et anticorps monoclonaux utiles pour le traitement des affections par le virus hiv et procedes de production de ces anticorps et de diagnostic de la presence de ce virus
ATE135743T1 (de) Monoklonale menschliche antikörper gegen hiv-i
FR2610631B1 (fr) Molecules comportant au moins une sequence peptidique porteuse d'un ou plusieurs, epitope caracteristique d'une proteine produite par p. falciparum dans les hepatocytes, et leurs utilisations, notamment pour le diagnostic du paludisme ou dans des compositions de vaccins contre le paludisme
NZ296564A (en) Method of improving antigenicity of antigens or haptens, fusion with rsv peptides; vaccines, vectors, nucleotides
ATE206620T1 (de) Menschliche, monoklonale antikörper gegen das transmembrane glycoprotein (gp41) des hiv-1, und verwandte peptide
DE69330352D1 (de) Mittel und methoden zur verbesserung der keratinocytenadhäsion an der haut
SE9000333D0 (sv) Monoklonal antikropp
ATE285418T1 (de) Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation
EP1104310A4 (fr) Expression et caracterisation d'une proteine d'enveloppe vih-1 associee a une reponse d'anticorps de neutralisation largement reactifs
RU94046321A (ru) Моноклональные муриновые антиидиотипические антитела, способ их получения и их применение, способы иммунизации и фармацевтический состав на их основе
HUP0003511A2 (hu) Hepatitisz-B-vírus polipeptidek
ATE247485T1 (de) Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
ATE134649T1 (de) Arzneimittel und verfahren zur behandlung von erworbenem immundefizienzsyndrom (aids) und aids- verwandtem komplex unter verwendung von karbohydratspezifischen antikörpern
RU93004854A (ru) Пептиды для вакцинации и индукции нейтрализующих антител против вируса иммунодефицита человека
FR2646607B1 (fr) Anticorps monoclonaux anti-b2 microglobuline
US20010007017A1 (en) Peptides which react with antibody representing the prognostic marker for hiv disease progression
Vahlne et al. Peptides for induction of neutralizing antibodies against human immunodeficiency virus
Buchacher Immortalisierung humaner peripherer B-Lymphozyten zur Produktion humaner monoklonaler Antikoerper (Humane monoklonale Antikoerper gegen HIV-1 zur passiven Immunisierung und Immuntherapie)